Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

AltaRex reacquires Western European marketing rights to Ovarex

Jan. 27, 1998

New approach to cancer therapy reported

Jan. 27, 1998

Vical receives patent protection for lipid-mediated DNA vaccines

Jan. 8, 1998

Mechanism of TNF-alpha production in tumor tissues by Ono-4007

Jan. 5, 1998

Favorable phase III trial results reported for HER2 monoclonal antibody

Dec. 31, 1997

Chiron's Proleukin recommended for approval for new indication

Dec. 23, 1997

New antitumor agent in development in China

Dec. 22, 1997

Idec's immunotherapy shows promise in phase I/II for non-Hodgkin's lymphoma

Dec. 22, 1997

MAb for non-Hodgkin's lymphoma now available in U.S.

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...